Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2026
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard TherapyLara Stepan, Sahar Ansari, Jeremy S Abramson, et al.
Blood|November 1, 2021
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideEphraim J Fuchs, Shannon R McCurdy, Scott R Solomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2020
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood TransplantScott R Solomon, Andrew St Martin, Mei-Jie Zhang, et al.
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Blood Advances|October 4, 2023
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysisHemant S Murthy, Mei-Jie Zhang, Karen Chen, et al.
Pageof 8